Neonatal Abstinence Syndrome Questions & Answers

1. National Association of State Alcohol and Drug Abuse Directors, Inc (NASADAD). Neonatal abstinence syndrome. June 2015. Available at http://nasadad.wpengine.com/wp-content/uploads/2015/06/NAS-Fact-Sheet-Final.pdf.

2. Stover MW, Davis JM. Opioids in pregnancy and neonatal abstinence syndrome. Semin Perinatol. 2015 Nov. 39(7):561-5. [QxMD MEDLINE Link].

3. Chana S, Anand K. Can we use methadone for analgesia in neonates?. Arch Dis Child Fetal Neonatal Ed. 2001. 85:79-81. [QxMD MEDLINE Link]. [Full Text].

4. Franck LS, Vilardi J, Durand D, Powers R. Opioid withdrawal in neonates after continuous infusions of morphine or fentanyl during extracorporeal membrane oxygenation. Am J Crit Care. 1998 Sep. 7(5):364-9. [QxMD MEDLINE Link].

5. Substance Abuse and Mental Health Services Administration (SAMHSA). Results from the 2013 National Survey on Drug Use & Health: summary of national findings. HHS publication no 14-4863. US Department of Health and Human Services. September 2014. Available at https://www.samhsa.gov/data/sites/default/files/NSDUHresultsPDFWHTML2013/Web/NSDUHresults2013.pdf.

6. Patrick SW, Schumacher RE, Benneyworth BD, Krans EE, McAllister JM, Davis MM. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. JAMA. 2012 May 9. 307(18):1934-40. [QxMD MEDLINE Link].

7. Hytinantti T, Kahila H, Renlund M, Jarvenpaa AL, Halmesmaki E, Kivitie-Kallio S. Neonatal outcome of 58 infants exposed to maternal buprenorphine in utero. Acta Paediatr. 2008 Aug. 97(8):1040-4. [QxMD MEDLINE Link].

8. Subedi L, Huang H, Pant A, et al. Plasma brain-derived neurotrophic factor levels in newborn infants with neonatal abstinence syndrome. Front Pediatr. 2017. 5:238. [QxMD MEDLINE Link].

9. Lim S, Prasad MR, Samuels P, Gardner DK, Cordero L. High-dose methadone in pregnant women and its effect on duration of neonatal abstinence syndrome. Am J Obstet Gynecol. 2009 Jan. 200(1):70.e1-5. [QxMD MEDLINE Link].

10. Dryden C, Young D, Hepburn M, Mactier H. Maternal methadone use in pregnancy: factors associated with the development of neonatal abstinence syndrome and implications for healthcare resources. BJOG. 2009 Apr. 116(5):665-71. [QxMD MEDLINE Link].

11. Wouldes TA, Woodward LJ. Maternal methadone dose during pregnancy and infant clinical outcome. Neurotoxicol Teratol. 2010 May-Jun. 32(3):406-13. [QxMD MEDLINE Link].

12. Cleary BJ, Eogan M, O'Connell MP, et al. Methadone and perinatal outcomes: a prospective cohort study. Addiction. 2012 Aug. 107(8):1482-92. [QxMD MEDLINE Link].

13. Minozzi S, Amato L, Bellisario C, Ferri M, Davoli M. Maintenance agonist treatments for opiate-dependent pregnant women. Cochrane Database Syst Rev. 2013. 12:CD006318. [QxMD MEDLINE Link].

14. National Institutes of Health. Buprenorphine treatment in pregnancy: less distress to babies. December 9, 2010. Available at http://www.nih.gov/news/health/dec2010/nida-09.htm.

15. Jones HE, Dengler E, Garrison A, et al. Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. Drug Alcohol Depend. 2014 Jan 1. 134:414-7. [QxMD MEDLINE Link].

16. Jansson LM, Velez ML, McConnell K, et al. Maternal buprenorphine treatment and infant outcome. Drug Alcohol Depend. 2017 Nov 1. 180:56-61. [QxMD MEDLINE Link].

17. O'Connor AB, Kelly BK, O'Brien LM. Maternal and infant outcomes following third trimester exposure to marijuana in opioid dependent pregnant women maintained on buprenorphine. Drug Alcohol Depend. 2017 Nov 1. 180:200-3. [QxMD MEDLINE Link].

18. Kandall SR. Treatment strategies for drug-exposed neonates. Clin Perinatol. 1999 Mar. 26(1):231-43. [QxMD MEDLINE Link].

19. Law KL, Stroud LR, LaGasse LL, et al. Smoking during pregnancy and newborn neurobehavior. Pediatrics. 2003 Jun. 111(6 Pt 1):1318-23. [QxMD MEDLINE Link]. [Full Text].

20. Haddad PM, Pal BR, Clarke P, Wieck A, Sridhiran S. Neonatal symptoms following maternal paroxetine treatment: serotonin toxicity or paroxetine discontinuation syndrome?. J Psychopharmacol. 2005 Sep. 19(5):554-7. [QxMD MEDLINE Link].

21. Bence C, Bonord A, Rebillard C, et al. Neonatal abstinence syndrome following tianeptine dependence during pregnancy. Pediatrics. 2016 Jan. 137(1):[QxMD MEDLINE Link].

22. Anand KJ, Campbell-Yeo M. Consequences of prenatal opioid use for newborns. Acta Paediatr. 2015 Nov. 104(11):1066-9. [QxMD MEDLINE Link].

23. Substance Abuse and Mental Health Services Administration. Results from the 2012 National Survey on Drug Use and Health: summary of national findings. HHS publication no 13-4795. US Department of Health and Human Services. September 2013. Available at http://www.samhsa.gov/data/NSDUH/2012SummNatFindDetTables/NationalFindings/NSDUHresults2012.htm#ch2.6.

24. Substance Abuse and Mental Health Services Administration (SAMHSA). Trends in substances of abuse among pregnant women and women of childbearing age in treatment. The TEDS Report. July 2013. Available at https://www.samhsa.gov/data/sites/default/files/spot110-trends-pregnant-women-2013.pdf.

25. Substance Abuse and Mental Health Services Administration (SAMHSA). Substance use among women during pregnancy and following childbirth. National Survey on Drug Use and Health: the NSDUH report. May 21, 2009. Available at https://www.openminds.com/wp-content/uploads/indres/052109nsduhpregnancysubabuse.pdf.

26. Cairns PA. Drug misuse: Conception into childhood. Current Paediatrics. 2001 December. 11(6):475-9.

27. Prentice S. Substance misuse in pregnancy. Obstetrics, Gynaecology & Reproductive Med. 2007 September. 17:272-7.

28. Gyarmathy VA, Giraudon I, Hedrich D, Montanari L, Guarita B, Wiessing L. Drug use and pregnancy - challenges for public health. Euro Surveill. 2009 Mar 5. 14(9):33-6. [QxMD MEDLINE Link]. [Full Text].

29. Finnegan L. Licit and illicit drug use during pregnancy: maternal, neonatal and early childhood consequences. Substance Abuse in Canada. 2013. Available at http://www.ccsa.ca/Resource%20Library/CCSA-Drug-Use-during-Pregnancy-Report-2013-en.pdf.

30. Uebel H, Wright IM, Burns L, et al. Epidemiological evidence for a decreasing incidence of neonatal abstinence syndrome, 2000-11. Paediatr Perinat Epidemiol. 2016 May. 30(3):267-73. [QxMD MEDLINE Link].

31. Substance Abuse and Mental Health Services Administration (SAMHSA). National Survey on Drug Use and Health: the NSDUH report. Substance use during pregnancy: 2002 and 2003 update. June 2, 2005. Available at http://archive.samhsa.gov/data/2k5/pregnancy/pregnancy.pdf.

32. Irner TB, Teasdale TW, Nielsen T, Vedal S, Olofsson M. Substance use during pregnancy and postnatal outcomes. J Addict Dis. 2012 Jan. 31(1):19-28. [QxMD MEDLINE Link].

33. Maguire D, Groer M. Neonatal abstinence syndrome and the gastrointestinal tract. Med Hypotheses. 2016 Dec. 97:11-15. [QxMD MEDLINE Link].

34. Gray KA, Day NL, Leech S, Richardson GA. Prenatal marijuana exposure: effect on child depressive symptoms at ten years of age. Neurotoxicol Teratol. 2005 May-Jun. 27(3):439-48. [QxMD MEDLINE Link].

35. Goldschmidt L, Day NL, Richardson GA. Effects of prenatal marijuana exposure on child behavior problems at age 10. Neurotoxicol Teratol. 2000 May-Jun. 22(3):325-36. [QxMD MEDLINE Link].

36. Lester BM, ElSohly M, Wright LL, et al. The Maternal Lifestyle Study: drug use by meconium toxicology and maternal self-report. Pediatrics. 2001 Feb. 107(2):309-17. [QxMD MEDLINE Link].

37. [Guideline] American Academy of Pediatrics Committee on Substance Abuse. Drug-exposed infants. Pediatr. 1995 Aug. 96(2 Pt 1):364-7. [QxMD MEDLINE Link].

38. Doberczak TM, Kandall SR, Wilets I. Neonatal opiate abstinence syndrome in term and preterm infants. J Pediatr. 1991 Jun. 118(6):933-7. [QxMD MEDLINE Link].

39. Liu AJ, Jones MP, Murray H, Cook CM, Nanan R. Perinatal risk factors for the neonatal abstinence syndrome in infants born to women on methadone maintenance therapy. Aust N Z J Obstet Gynaecol. 2010 Jun. 50(3):253-8. [QxMD MEDLINE Link].

40. [Guideline] Hudak ML, Tan RC; Committee on Drugs; Committee on Fetus and Newborn; American Academy of Pediatrics. Neonatal drug withdrawal. Pediatrics. 2012 Feb. 129(2):e540-60. [QxMD MEDLINE Link]. [Full Text].

41. Finnegan LP. Neonatal abstinence syndrome: assessment and pharmacolotherapy. Neonatal therapy: An update. New York, NY: Excerpta Medica; 1986. 122-46.

42. Ostrea EM, Ostrea AR, Simpson PM. Mortality within the first 2 years in infants exposed to cocaine, opiate, or cannabinoid during gestation. Pediatrics. 1997 Jul. 100(1):79-83. [QxMD MEDLINE Link]. [Full Text].

43. Lester BM, Tronick EZ. History and description of the Neonatal Intensive Care Unit Network Neurobehavioral Scale. Pediatrics. 2004 Mar. 113(3 Pt 2):634-40. [QxMD MEDLINE Link].

44. Timpson W, Killoran C, Maranda L, Picarillo A, Bloch-Salisbury E. A quality improvement initiative to increase scoring consistency and accuracy of the Finnegan tool: challenges in obtaining reliable assessments of drug withdrawal in neonatal abstinence syndrome. Adv Neonatal Care. 2018 Feb. 18(1):70-8. [QxMD MEDLINE Link]. [Full Text].

45. Grossman MR, Lipshaw MJ, Osborn RR, Berkwitt AK. A novel approach to assessing infants with neonatal abstinence syndrome. Hosp Pediatr. 2018 Jan. 8(1):1-6. [QxMD MEDLINE Link].

46. Young LW, Ounpraseuth ST, Merhar SL, et al, for the ACT NOW Collaborative. Eat, Sleep, Console approach or usual care for neonatal opioid withdrawal. N Engl J Med. 2023 Apr 30. [QxMD MEDLINE Link].

47. Nicholson S, Waskosky A. The Eat, Sleep, Console method: a literature review. Neonatal Netw. 2022 Nov 11. 41(6):333-40. [QxMD MEDLINE Link].

48. US Department of Health and Human Services. The Child Abuse Prevention and Treatment Act: including adoption opportunities & the Abandoned Infants Assistance Act. As amended by the Keeping Children and Families Safe Act of 2003. June 25, 2003. Available at https://www.acf.hhs.gov/sites/default/files/cb/capta2003.pdf.

49. Jaudes PK, Ekwo E, Van Voorhis J. Association of drug abuse and child abuse. Child Abuse Negl. 1995 Sep. 19(9):1065-75. [QxMD MEDLINE Link].

50. Smith DK, Johnson AB, Pears KC, Fisher PA, DeGarmo DS. Child maltreatment and foster care: unpacking the effects of prenatal and postnatal parental substance use. Child Maltreat. 2007 May. 12(2):150-60. [QxMD MEDLINE Link].

51. Bahwere P, Haumont D, Delange F. Congenital hypothyroidism and neonatal withdrawal syndrome. Eur J Pediatr. 1996 Nov. 155(11):937-8. [QxMD MEDLINE Link].

52. Chasnoff IJ. Prenatal substance abuse. Neoreviews. 2003. 4(9):e228-e235.

53. Colby JM. Comparison of umbilical cord tissue and meconium for the confirmation of in utero drug exposure. Clin Biochem. 2017 Sep. 50(13-14):784-90. [QxMD MEDLINE Link].

54. Montgomery DP, Plate CA, Jones M, et al. Using umbilical cord tissue to detect fetal exposure to illicit drugs: a multicentered study in Utah and New Jersey. J Perinatol. 2008 Nov. 28(11):750-3. [QxMD MEDLINE Link].

55. Kassima Z, Greenough A. Neonatal abstinence syndrome: identification and management. Curr Paediatrics. 2006 June. 16:172-5.

56. Jones JT, Jones M, Jones B, Sulaiman K, Plate C, Lewis D. Detection of codeine, morphine, 6-monoacetylmorphine, and meconin in human umbilical cord tissue: method validation and evidence of in utero heroin exposure. Ther Drug Monit. 2015 Feb. 37(1):45-52. [QxMD MEDLINE Link]. [Full Text].

57. Palmer KL, Wood KE, Krasowski MD. Evaluating a switch from meconium to umbilical cord tissue for newborn drug testing: A retrospective study at an academic medical center. Clin Biochem. 2017 Apr. 50(6):255-61. [QxMD MEDLINE Link].

58. Gray T, Huestis M. Bioanalytical procedures for monitoring in utero drug exposure. Anal Bioanal Chem. 2007 Aug. 388(7):1455-65. [QxMD MEDLINE Link].

59. Frank DA, McCarten KM, Robson CD, et al. Level of in utero cocaine exposure and neonatal ultrasound findings. Pediatrics. 1999 Nov. 104(5 Pt 1):1101-5. [QxMD MEDLINE Link]. [Full Text].

60. van Huis M, van Kempen AA, Peelen M, et al. Brain ultrasonography findings in neonates with exposure to cocaine during pregnancy. Pediatr Radiol. 2009 Mar. 39(3):232-8. [QxMD MEDLINE Link].

61. Rivkin MJ, Davis PE, Lemaster JL, et al. Volumetric MRI study of brain in children with intrauterine exposure to cocaine, alcohol, tobacco, and marijuana. Pediatrics. 2008 Apr. 121(4):741-50. [QxMD MEDLINE Link]. [Full Text].

62. Gibson KS, Stark S, Kumar D, Bailit JL. The relationship between gestational age and the severity of neonatal abstinence syndrome. Addiction. 2017 Apr. 112(4):711-16. [QxMD MEDLINE Link].

63. [Guideline] Jansson LM, Choo R, Velez ML, et al. Methadone maintenance and breastfeeding in the neonatal period. Pediatrics. 2008 Jan. 121(1):106-14. [QxMD MEDLINE Link].

64. [Guideline] American Academy of Pediatrics Committee on Drugs. Neonatal drug withdrawal. [published erratum appears in Pediatrics 1998 Sep;102(3 Pt 1):660]. Pediatrics. 1998 Jun. 101(6):1079-88. [QxMD MEDLINE Link].

65. [Guideline] American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001 Sep. 108(3):776-89. [QxMD MEDLINE Link].

66. ACOG Committee on Health Care for Underserved Women; American Society of Addiction Medicine. ACOG Committee Opinion No. 524: Opioid abuse, dependence, and addiction in pregnancy. Obstet Gynecol. 2012 May. 119(5):1070-6. [QxMD MEDLINE Link]. [Full Text].

67. Burgos AE, Burke BL Jr. Neonatal abstinence syndrome. NeoReviews. 2009. 10(5):e222-e229.

68. Hale TW. Pharmacology review: drug therapy and breastfeeding: antidepressants, antipsychotics, antimanics, and sedatives. NeoReviews. May 2004. e451-e456.

69. [Guideline] Substance Abuse and Mental Health Services Administration. Guidance for Treating Pregnant and Parenting Women With Opioid Use Disorder and Their Infants. Rockville, MD: SAMHSA; 2018. (SMA)18-5054: [Full Text].

70. Lainwala S, Brown ER, Weinschenk NP, Blackwell MT, Hagadorn JI. A retrospective study of length of hospital stay in infants treated for neonatal abstinence syndrome with methadone versus oral morphine preparations. Adv Neonatal Care. 2005 Oct. 5(5):265-72. [QxMD MEDLINE Link].

71. McKnight S, Coo H, Davies G, et al. Rooming-in for infants at risk of neonatal abstinence syndrome. Am J Perinatol. 2016 Apr. 33(5):495-501. [QxMD MEDLINE Link].

72. Holmes AV, Atwood EC, Whalen B, et al. Rooming-in to treat neonatal abstinence syndrome: improved family-centered care at lower cost. Pediatrics. 2016 Jun. 137(6):[QxMD MEDLINE Link].

73. McQueen K, Murphy-Oikonen J. Neonatal abstinence syndrome. N Engl J Med. 2016 Dec 22. 375(25):2468-79. [QxMD MEDLINE Link]. [Full Text].

74. Jackson HJ, Lopez C, Miller S, Engelhardt B. A scoping review of acupuncture as a potential intervention for neonatal abstinence syndrome. Med Acupunct. 2019 Apr 1. 31(2):69-84. [QxMD MEDLINE Link]. [Full Text].

75. Young ME, Hager SJ, Spurlock D Jr. Retrospective chart review comparing morphine and methadone in neonates treated for neonatal abstinence syndrome. Am J Health Syst Pharm. 2015 Dec 1. 72(23 suppl 3):S162-7. [QxMD MEDLINE Link].

76. Brown MS, Hayes MJ, Thornton LM. Methadone versus morphine for treatment of neonatal abstinence syndrome: a prospective randomized clinical trial. J Perinatol. 2015 Apr. 35(4):278-83. [QxMD MEDLINE Link].

77. Davis JM, Shenberger J, Terrin N, et al. Comparison of safety and efficacy of methadone vs morphine for treatment of neonatal abstinence syndrome: a randomized clinical trial. JAMA Pediatr. 2018 Aug 1. 172(8):741-8. [QxMD MEDLINE Link]. [Full Text].

78. Hall ES, Isemann BT, Wexelblatt SL, et al. A cohort comparison of buprenorphine versus methadone treatment for neonatal abstinence syndrome. J Pediatr. 2016 Mar. 170:39-44.e1. [QxMD MEDLINE Link].

79. Mucke S, Nagel M, Siedentopf J, Buhrer C, Huseman D. Neonatal abstinence syndrome: twelve years of experience at a regional referral center. Klin Padiatr. 2017 Jan. 229(1):32-9. [QxMD MEDLINE Link].

80. Tolia VN, Murthy K, Bennett MM, et al. Antenatal methadone vs buprenorphine exposure and length of hospital stay in infants admitted to the intensive care unit with neonatal abstinence syndrome. J Perinatol. 2018 Jan. 38(1):75-9. [QxMD MEDLINE Link].

81. Kraft WK, Adeniyi-Jones SC, Chervoneva I, et al. Buprenorphine for the treatment of the neonatal abstinence syndrome. N Engl J Med. 2017 Jun 15. 376(24):2341-8. [QxMD MEDLINE Link]. [Full Text].

82. Wachman EM, Hayes MJ, Sherva R, et al. Variations in opioid receptor genes in neonatal abstinence syndrome. Drug Alcohol Depend. 2015 Oct 1. 155:253-9. [QxMD MEDLINE Link].

83. Wachman EM, Hayes MJ, Brown MS, et al. Association of OPRM1 and COMT single-nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome. JAMA. 2013 May 1. 309(17):1821-7. [QxMD MEDLINE Link].

84. Ryan G, Dooley J, Gerber Finn L, Kelly L. Nonpharmacological management of neonatal abstinence syndrome: a review of the literature. J Matern Fetal Neonatal Med. 2019 May. 32(10):1735-40. [QxMD MEDLINE Link].

85. Hall ES, Wexelblatt SL, Crowley M, et al. A multicenter cohort study of treatments and hospital outcomes in neonatal abstinence syndrome. Pediatrics. 2014 Aug. 134(2):e527-34. [QxMD MEDLINE Link].

86. Saiki T, Lee S, Hannam S, Greenough A. Neonatal abstinence syndrome--postnatal ward versus neonatal unit management. Eur J Pediatr. 2010 Jan. 169(1):95-8. [QxMD MEDLINE Link].

87. Backes CH, Backes CR, Gardner D, Nankervis CA, Giannone PJ, Cordero L. Neonatal abstinence syndrome: transitioning methadone-treated infants from an inpatient to an outpatient setting. J Perinatol. 2012 Jun. 32(6):425-30. [QxMD MEDLINE Link]. [Full Text].

88. Jansson LM. ABM clinical protocol #21: Guidelines for breastfeeding and the drug-dependent woman. Breastfeed Med. 2009 Dec. 4(4):225-8. [QxMD MEDLINE Link]. [Full Text].

89. Grim K, Harrison TE, Wilder RT. Management of neonatal abstinence syndrome from opioids. Clin Perinatol. 2013 Sep. 40(3):509-24. [QxMD MEDLINE Link].

90. Agthe AG, Kim GR, Mathias KB, et al. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics. 2009 May. 123(5):e849-56. [QxMD MEDLINE Link]. [Full Text].

91. Sarkar S, Donn SM. Management of neonatal abstinence syndrome in neonatal intensive care units: a national survey. J Perinatol. 2006 Jan 1. 26(1):15-7. [QxMD MEDLINE Link].

92. Mazurier E, Cambonie G, Barbotte E, Grare A, Pinzani V, Picaud JC. Comparison of chlorpromazine versus morphine hydrochloride for treatment of neonatal abstinence syndrome. Acta Paediatr. 2008 Oct. 97(10):1358-61. [QxMD MEDLINE Link].

93. HR2634 - Drug Addiction Treatment Act of 2000 (DATA 2000). Congress.gov. July 27, 2000. Available at https://www.congress.gov/bill/106th-congress/house-bill/2634. Accessed: December 20, 2017.

94. Kraft WK, Gibson E, Dysart K, et al. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics. 2008 Sep. 122(3):e601-7. [QxMD MEDLINE Link]. [Full Text].

Ashraf H Hamdan, MD, MBBCh, MSc, MRCP, FAAP Adjunct Associate Clinical Professor of Pediatrics, Vanderbilt University Medical Center; Neonatologist, Pediatrix Medical Group of Nashville

Ashraf H Hamdan, MD, MBBCh, MSc, MRCP, FAAP is a member of the following medical societies: American Academy of Pediatrics

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Brian S Carter, MD, FAAP Professor of Pediatrics, University of Missouri-Kansas City School of Medicine; Attending Physician, Division of Neonatology, Children's Mercy Hospital and Clinics; Faculty, Children's Mercy Bioethics Center

Brian S Carter, MD, FAAP is a member of the following medical societies: Alpha Omega Alpha, American Academy of Hospice and Palliative Medicine, American Academy of Pediatrics, American Pediatric Society, American Society for Bioethics and Humanities, American Society of Law, Medicine & Ethics, Society for Pediatric Research, National Hospice and Palliative Care Organization

Disclosure: Nothing to disclose.

Santina A Zanelli, MD Associate Professor, Department of Pediatrics, Division of Neonatology, University of Virginia Health System

Santina A Zanelli, MD is a member of the following medical societies: American Academy of Pediatrics, American Epilepsy Society, Society for Neuroscience, Society for Pediatric Research

Disclosure: Nothing to disclose.

Scott S MacGilvray, MD Clinical Professor, Department of Pediatrics, Division of Neonatology, The Brody School of Medicine at East Carolina University

Scott S MacGilvray, MD is a member of the following medical societies: American Academy of Pediatrics

Disclosure: Nothing to disclose.

The authors and editors of Medscape Drugs & Diseases, gratefully acknowledge the contributions of previous authors Jaques Belik, MD, and Judy Hawes, RN, MN, to the writing and development of this article.

• Print this section
• Print the entire contents of
• Print the entire contents of article